Vitroscope is a leading brand in the field of biomedical science, providing advanced technology and solutions for life science research in both academia and industry. They aim to revolutionize the research landscape by developing cutting-edge technology that allows for the observation of biological processes in real-time within tissue context over extended periods. Founded in 2019, Vitroscope originated from five years of research at the Norwegian University of Science and Technology in collaboration with the University of Zurich.

The COVID-19 pandemic and the subsequent challenges with remote work further emphasized the need for accurate early-stage clinical research, affirming Vitroscope's AI-native approach. With a team of passionate experts, including Co-founders and CEOs Carlo Kriesi and Heikki Sjöman, along with Scientific Lead Vendela Schjetne, Vitroscope is dedicated to advancing active health and disease resolution. They leverage their expertise in bioinformatics, mechanical engineering, and IoT applications to create innovative solutions.

Vitroscope's vision aligns with recent scientific advancements that offer alternatives to animal testing. They aim to provide enabling technologies that support the submission of non-animal data in complying with the FDA Modernization Act 2. 0.

Supported by a team of advisors from academia and industry, including industry advisor Marco Fritzsche, scientific advisor Prof. Magnar Bjørås, and biomedical industry advisor Gayle Lee, Vitroscope ensures quality and expertise in their offerings. Overall, Vitroscope is committed to transforming the life science research landscape through advanced technology and solutions that provide accurate and impactful insights for the advancement of human health